WO2007100695A3 - Metabolic regulators and uses thereof - Google Patents

Metabolic regulators and uses thereof Download PDF

Info

Publication number
WO2007100695A3
WO2007100695A3 PCT/US2007/004793 US2007004793W WO2007100695A3 WO 2007100695 A3 WO2007100695 A3 WO 2007100695A3 US 2007004793 W US2007004793 W US 2007004793W WO 2007100695 A3 WO2007100695 A3 WO 2007100695A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
metabolic
present
regulators
affect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/004793
Other languages
French (fr)
Other versions
WO2007100695A2 (en
WO2007100695A9 (en
Inventor
Kenneth Walsh
Noriyuki Ouchi
Ling Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Priority to US12/280,961 priority Critical patent/US20090142336A1/en
Priority to CA002644046A priority patent/CA2644046A1/en
Priority to AU2007221245A priority patent/AU2007221245A1/en
Priority to JP2008557309A priority patent/JP2009528355A/en
Priority to EP07751545A priority patent/EP1996215A2/en
Publication of WO2007100695A2 publication Critical patent/WO2007100695A2/en
Publication of WO2007100695A3 publication Critical patent/WO2007100695A3/en
Anticipated expiration legal-status Critical
Publication of WO2007100695A9 publication Critical patent/WO2007100695A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)

Abstract

The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a pharmaceutical composition comprising an agent, where the agent activates or inhibits the activity and/or gene expression of the metabolic regulator. The metabolic regulators of the present invention are, for example MSPl (2160028F08Rik; SEQ ID NO: 16); MSP2 (2310043I08Rik; SEQ ID NO: 17); MSP3 (NM_026754;l 110017116Rik;SEQ ID NO: 1); MSP4 (4732466D17Rik; SEQ BD NO:18); MSP 5 (NM_024237; 1600015H20Rik; SEQ ID NO:12); Insl6 (AF_156094; SEQ ID NO:20). The present invention also provides methods to screen for agents that affect the metabolic regulators of the present invention.
PCT/US2007/004793 2006-02-28 2007-02-23 Metabolic regulators and uses thereof Ceased WO2007100695A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/280,961 US20090142336A1 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof
CA002644046A CA2644046A1 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof
AU2007221245A AU2007221245A1 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof
JP2008557309A JP2009528355A (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof
EP07751545A EP1996215A2 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77765406P 2006-02-28 2006-02-28
US60/777,654 2006-02-28

Publications (3)

Publication Number Publication Date
WO2007100695A2 WO2007100695A2 (en) 2007-09-07
WO2007100695A3 true WO2007100695A3 (en) 2008-08-21
WO2007100695A9 WO2007100695A9 (en) 2008-12-31

Family

ID=38459584

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/004793 Ceased WO2007100695A2 (en) 2006-02-28 2007-02-23 Metabolic regulators and uses thereof
PCT/US2007/004835 Ceased WO2007100722A2 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004835 Ceased WO2007100722A2 (en) 2006-02-28 2007-02-23 Methods to identify factors associated with muscle growth and uses thereof

Country Status (7)

Country Link
US (2) US20090142336A1 (en)
EP (2) EP1996216A2 (en)
JP (1) JP2009528355A (en)
KR (1) KR20080108487A (en)
AU (2) AU2007221245A1 (en)
CA (2) CA2644057A1 (en)
WO (2) WO2007100695A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
US8895002B2 (en) 2007-04-09 2014-11-25 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
NZ590050A (en) 2008-06-04 2012-08-31 Amgen Inc Fgf21 mutants and uses thereof
WO2010042747A2 (en) 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
JO3469B1 (en) 2009-05-05 2020-07-05 Amgen Inc FGF21 mutants and their uses
JP2012530493A (en) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド Chimeric polypeptides and uses thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
RU2631597C2 (en) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Compositions and methods for metabolic pathway modulation
KR101330448B1 (en) * 2011-09-06 2013-11-15 고려대학교 산학협력단 Method for regulation of metabolic homeostasis, stress resistance, and lifespan by the endogenous siRNA(endo-siRNA) pathway
WO2013090318A1 (en) * 2011-12-12 2013-06-20 Trustees Of Boston University Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases
RU2014129907A (en) * 2011-12-19 2016-02-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД MEMBRANE HIV FUSION INHIBITORS
DK3381461T3 (en) 2012-01-09 2021-05-17 Serpin Pharma Llc PEPTIDES AND PROCEDURES FOR USING IT
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
CN102807993B (en) * 2012-08-31 2014-04-09 西北农林科技大学 Skeletal muscle specific miRNA expression vector and reconstitution cell of target Myostatin gene
EP2919772B1 (en) 2012-11-13 2019-03-27 NuSirt Sciences, Inc. Pde5 inhibitors and leucine or a leucine metabolite for use in the treatment of diabetes
WO2014113404A1 (en) 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
CA2928726A1 (en) 2013-10-30 2015-05-07 The Curators Of The University Of Missouri Method for scalable skeletal muscle lineage specification and cultivation
KR20160119863A (en) 2014-02-27 2016-10-14 뉴서트 사이언시스, 인크. Compositions and methods for the reduction or prevention of hepatic steatosis
FR3021318B1 (en) * 2014-05-20 2017-04-28 Inst Biophytis 20-HYDROXYECDYSONE-DERIVED PRODUCTS AND THEIR USE IN THE PREPARATION OF MEDICAMENTS
EP3108893A1 (en) * 2015-06-25 2016-12-28 Universite Claude Bernard - Lyon 1 Novel therapeutic use of fgf19
CN108366985B (en) 2015-08-28 2021-06-18 赛品制药有限责任公司 Methods for the treatment of diseases
CA3002676A1 (en) * 2015-10-29 2017-05-04 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
WO2018208628A1 (en) 2017-05-06 2018-11-15 Memphis Meats, Inc. Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
US11479792B2 (en) 2017-07-13 2022-10-25 Upside Foods, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
US10869465B2 (en) * 2017-08-10 2020-12-22 Osaka University Transgenic mouse model of retinal vascular disease, method of making, and method of using
WO2019060702A1 (en) * 2017-09-22 2019-03-28 Wayne State University Systems and methods to detect stress leading to miscarriage risk
CA3226361A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
CN113509471B (en) * 2021-07-19 2023-06-13 中国药科大学 Application of AKT2 inhibitor in preparation of medicine for treating myocardial injury induced by doxorubicin
CN114213518B (en) * 2021-12-27 2023-04-18 北京大学 Tmem52 protein for regulating glycolipid metabolism, coding gene, sgRNA and application thereof
IL317311A (en) 2022-06-07 2025-01-01 Upside Foods Inc Engineering cell lines capable of proliferation in growth factor free media formulations
CN116554294B (en) * 2023-04-27 2024-03-15 北京大学 Tmem52 protein fragments, coding genes, recombinant vectors, recombinant microorganisms and their applications
CN116784275B (en) * 2023-08-11 2025-06-27 成都药康生物科技有限公司 Construction method and application of animal model of hepatic fibrosis or nonalcoholic steatohepatitis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020025A2 (en) * 1998-10-02 2000-04-13 St. Elizabeth's Medical Center, Inc. Akt compositions for enhancing survival of cells
WO2001093806A2 (en) * 2000-06-08 2001-12-13 St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS
WO2002100898A2 (en) * 2001-06-11 2002-12-19 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0918859A1 (en) * 1996-08-02 1999-06-02 ZymoGenetics, Inc. Testis-specific insulin homolog polypeptides
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US20030144204A1 (en) * 2001-12-19 2003-07-31 Baylor College Of Medicine Akt-based inducible survival switch
US7314911B2 (en) * 2004-08-17 2008-01-01 Board Of Regents, The University Of Texas System Prostate hyperplasia therapy
US20080104718A1 (en) * 2004-11-08 2008-05-01 University Of Rochester Transgenic Non-Human Animal Models of Ischemia-Reperfusion Injury and Uses Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020025A2 (en) * 1998-10-02 2000-04-13 St. Elizabeth's Medical Center, Inc. Akt compositions for enhancing survival of cells
WO2001093806A2 (en) * 2000-06-08 2001-12-13 St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS
WO2002100898A2 (en) * 2001-06-11 2002-12-19 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHIEKOFER STEPHAN ET AL: "Microarray cDNA profiles of acute and chronic Akt1 activation in transgenic mouse hearts reveal gene expression profiles associated with compensatory hypertrophy and failure", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 108, no. 17, suppl, 28 October 2003 (2003-10-28), pages 77, XP009096303, ISSN: 0009-7322 *
SKURK CARSTEN ET AL: "The Akt-FOXO signaling axis controls heart size by regulating expression of the ubiquitin ligase atrogin", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 110, no. 17, suppl, 26 October 2004 (2004-10-26), pages 44, XP009096296, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
JP2009528355A (en) 2009-08-06
EP1996216A2 (en) 2008-12-03
US20090142336A1 (en) 2009-06-04
KR20080108487A (en) 2008-12-15
CA2644057A1 (en) 2007-09-07
WO2007100695A2 (en) 2007-09-07
WO2007100722A2 (en) 2007-09-07
WO2007100722A3 (en) 2008-12-18
EP1996215A2 (en) 2008-12-03
WO2007100695A9 (en) 2008-12-31
CA2644046A1 (en) 2007-09-07
US20110191871A1 (en) 2011-08-04
AU2007221245A1 (en) 2007-09-07
AU2007221177A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2007100695A3 (en) Metabolic regulators and uses thereof
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2009048072A1 (en) ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
SG151329A1 (en) Amido compounds and their use as pharmaceuticals
WO2007038138A3 (en) Amido compounds and their use as pharmaceuticals
SG163518A1 (en) Amido compounds and their use as pharmaceuticals
WO2007022518A8 (en) New uses of glucoregulatory proteins
WO2004028516A3 (en) Compositions for the inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases
WO2008054208A3 (en) Use of nutritional compositions for preventing disorders
WO2008043087A3 (en) Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
NO20083104L (en) Solid preparation
WO2008098180A3 (en) Complementary personal lubrificant compositions and delivery system
WO2008068422A3 (en) Cosmetic use of a protein belonging to the ribonuclease family<0}
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
WO2012044745A3 (en) Personal care composition containing yeast extract and hexapeptide
WO2008058355A3 (en) Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
WO2008058358A3 (en) Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases.
Ma et al. Chronic aerobic exercise training alleviates myocardial fibrosis in aged rats through restoring bioavailability of hydrogen sulfide
GB2460378A (en) Non magnetic cobalt-palladium dental alloy
NO20090205L (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2010088430A3 (en) Methods for improving skin quality using rinse-off personal care compositions with variable amounts of hydrophobic benefit agents
WO2007110173A3 (en) Fungicidal active substance combinations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007221245

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12280961

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008557309

Country of ref document: JP

Ref document number: 2644046

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007221245

Country of ref document: AU

Date of ref document: 20070223

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 5193/CHENP/2008

Country of ref document: IN

Ref document number: 1020087023522

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007751545

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07751545

Country of ref document: EP

Kind code of ref document: A2